The ASX biotech sector lost about 7% of its value in May. But not every stock lagged and hopes for a rebound abound.
Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results